Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
Simone Nicolardi
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
Elena Domínguez-Vega
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
Anna-Katharina Heidenreich
Pharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany
Gestur Vidarsson
Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Dietmar Reusch
Pharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany
Markus Haberger
Pharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany
Manfred Wuhrer
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
David Falck
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
Determination of the impact of individual antibody glycoforms on FcɣRIIIa affinity, and consequently antibody-dependent cell-mediated cytotoxicity (ADCC) previously required high purity glycoengineering. We hyphenated FcɣRIIIa affinity chromatography to mass spectrometry, which allowed direct affinity comparison of glycoforms of intact monoclonal antibodies. The approach enabled reproduction and refinement of known glycosylation effects, and insights on afucosylation pairing as well as on low-abundant, unstudied glycoforms. Our method greatly improves the understanding of individual glycoform structure–function relationships. Thus, it is highly relevant for assessing Fc-glycosylation critical quality attributes related to ADCC.